Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Davide Guerrieri

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
Learning & Memory (Cold Spring Harbor, N.Y.)|January 21, 2014
AMPK agonist AICAR improves cognition and motor coordination in young and aged miceTali Kobilo, Davide Guerrieri, Yongqing Zhang, et al.
Immunotherapy|February 19, 2026
Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trialNeil Betteridge, Andrew Blauvelt, Colin Edgerton, et al.
The AAPS Journal|December 17, 2025
Substantial Comparability of Singlicate Versus Duplicate Analysis-A Retrospective Evaluation of Clinical Immunogenicity in a Biosimilar PK StudyMaike Lichtenfels, Jamie Fan, Davide Guerrieri, et al.
Diagnostics (Basel, Switzerland)|September 13, 2025
Sella Turcica and Cranial Base Symmetry in Anterior Synostotic Plagiocephaly Patients: A Retrospective Case-Control StudyEdoardo Staderini, Davide Guerrieri, Michele Tepedino, et al.
Expert Opinion on Biological Therapy|August 30, 2022
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilarOliver von Richter, Terry O'Reilly, Davide Guerrieri, et al.
Gynecologic Oncology|December 25, 2009
Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell linesGaetano Marverti, Alessio Ligabue, Davide Guerrieri, et al.
Bioorganic & Medicinal Chemistry|October 19, 2010
Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitorsEmanuele Carosati, Gianluca Sforna, Massimiliano Pippi, et al.
Expert Opinion on Biological Therapy|November 15, 2024
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studiesLena Lemke, Andrew Blauvelt, Ines Brückmann, et al.
European Journal of Pharmacology|May 19, 2009
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cellsGaetano Marverti, Alessio Ligabue, Giuseppe Paglietti, et al.
Investigational New Drugs|October 17, 2009
Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cellsGaetano Marverti, Alessio Ligabue, Monica Montanari, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Learning & Memory (Cold Spring Harbor, N.Y.)|January 21, 2014
AMPK agonist AICAR improves cognition and motor coordination in young and aged miceTali Kobilo, Davide Guerrieri, Yongqing Zhang, et al.
Immunotherapy|February 19, 2026
Comparison of treatment with GP2017 (an adalimumab biosimilar) and reference adalimumab in people with plaque psoriasis: a plain language summary of the ADACCESS trialNeil Betteridge, Andrew Blauvelt, Colin Edgerton, et al.
The AAPS Journal|December 17, 2025
Substantial Comparability of Singlicate Versus Duplicate Analysis-A Retrospective Evaluation of Clinical Immunogenicity in a Biosimilar PK StudyMaike Lichtenfels, Jamie Fan, Davide Guerrieri, et al.
Diagnostics (Basel, Switzerland)|September 13, 2025
Sella Turcica and Cranial Base Symmetry in Anterior Synostotic Plagiocephaly Patients: A Retrospective Case-Control StudyEdoardo Staderini, Davide Guerrieri, Michele Tepedino, et al.
Expert Opinion on Biological Therapy|August 30, 2022
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilarOliver von Richter, Terry O'Reilly, Davide Guerrieri, et al.
Gynecologic Oncology|December 25, 2009
Spermidine/spermine N1-acetyltranferase modulation by novel folate cycle inhibitors in cisplatin-sensitive and -resistant human ovarian cancer cell linesGaetano Marverti, Alessio Ligabue, Davide Guerrieri, et al.
Bioorganic & Medicinal Chemistry|October 19, 2010
Ligand-based virtual screening and ADME-tox guided approach to identify triazolo-quinoxalines as folate cycle inhibitorsEmanuele Carosati, Gianluca Sforna, Massimiliano Pippi, et al.
Expert Opinion on Biological Therapy|November 15, 2024
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studiesLena Lemke, Andrew Blauvelt, Ines Brückmann, et al.
European Journal of Pharmacology|May 19, 2009
Collateral sensitivity to novel thymidylate synthase inhibitors correlates with folate cycle enzymes impairment in cisplatin-resistant human ovarian cancer cellsGaetano Marverti, Alessio Ligabue, Giuseppe Paglietti, et al.
Investigational New Drugs|October 17, 2009
Characterization of the cell growth inhibitory effects of a novel DNA-intercalating bipyridyl-thiourea-Pt(II) complex in cisplatin-sensitive and -resistant human ovarian cancer cellsGaetano Marverti, Alessio Ligabue, Monica Montanari, et al.
Pageof 3